New FDA Approval of Kadcyla

25 Feb 2013 10:17 AM | Lori Aubrey (Administrator)

FDA approves Roche's Kadcyla (trastuzumab emtansine), the first antibody-drug conjugate for treating HER2-positive metastatic breast cancer.

Read about this and other approvals on our approvals page at


Northern New England Clinical Oncology Society
P.O. Box 643
Sandown, NH 03873-0643
Telephone (603) 887-1948

This website brought to you by:

Powered by Wild Apricot Membership Software